Cancer biotech Syndax Pharmaceuticals sets terms for $60 million IPO


Shutterstock photo

Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for resistant breast cancer, announced terms for its IPO on Thursday. The Waltham, MA-based company plans to raise $60 million by offering 4.3 million shares at a price range of $13 to $15. At the midpoint of the proposed range, it would command a fully diluted market value of $179 million. Syndax Pharmaceuticals, which was founded in 2005, plans to list on the NASDAQ under the symbol SNDX. It initially filed confidentially on November 15, 2013. Deutsche Bank and Jefferies are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:








Research Brokers before you trade

Want to trade FX?





Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com